Accordingly, therapeutics directed towards epigenetic mechanisms, involving for instance DNA methyltransferase (DNMT) and histone deacetylase (HDAC) inhibitors, have had some clinical success when applied to MDS and AML [2-6]. Here, DNMT1 is linked to myelodysplastic syndrome.